


Felix: A unique device to treat male infertility



Memphasys

ASX: MEM



Memphasys Value Proposition




- ✓ Revolutionary, proven technology for improved IVF treatment
- ✓ Addressing the significant global IVF services market -anticipated to **grow from ~US\$13.7 billion in 2019 to ~\$26.4 billion by 2026¹**
- ✓ First-mover advantage for bio separations technology
- ✓ Backed by industry experts and leaders in the field

1. Global IVF Services Market Revenue, By End User, 2018 – 2026, Global IVF Services Market Report – Allied Market Research (April 2019)

Current IVF Methods

Memphasys


- No standard method for IVF
- Average of 2.2 tries before success
- Common methods are:
 - Swim-up
 - Density Gradient Centrifugation (DCG)
 - Combination of both
- **Expensive with costs between \$80 to \$100 per cycle**
- Each method takes an average above 30 minutes to complete
- Laborious process involving machines and extensive manual labour
- Process can select DNA damaged cells reducing effectiveness



The Felix Device

Memphasys

- Gentle electric force applied to cartridge sample
- Best quality sperm attracted to negative charge
- Sperm separates through polymer membranes to:
 - Regulate cell size
 - Remove dead cells
 - Eliminate other debris
- Can be completed in 3 minutes (post 3 minute hydration time)
- No DNA damage
- Simple non-invasive process



Developed with global fertility expert Dr John Aitken

Memphasys



Key Milestones



- ✓ Successfully raised \$4.2 million to support KOL rollout with cornerstone support from major shareholders Andrew Goodall and prominent thoroughbred breeder and trainer Bob Peters
- ✓ Memphasys in conjunction with UNSW and Newcastle University awarded 3 year A\$549,452 ARC Linkage Grant
- ✓ 14 KOLs from across Europe, North America, the Middle East, India and Australia secured for in-vitro assessments
- ✓ Cartridges and consoles for the KOL assessment program in production with devices received by Monash IVF and University of Newcastle ahead of wider rollout
- ✓ +200 cartridges produced with +2,000 to be delivered in December
- ✓ Verification commencing now and is expected to be complete by year end
- ✓ Validation, which follows, is expected to be completed by mid-2020

Pathway to Market

- **Commercial sales expected to occur in mid to late 2020**
(subject to meeting any requisite legal and regulatory certifications and gaining market support by KOLs in specific targeted jurisdictions for the use of the Felix device in their clinics/ andrology centres)
- **Initial commercial pathway to focus on selected countries aligned to the Company's commercialisation objectives**
- **Countries include:**
 - Japan
 - India
 - Canada
 - Iran
 - New Zealand



Pathway to Market

Memphasys

Country	Fresh IVF cycles in 2018	Expected fresh IVF cycles by 2026	KOL in market (Y/N)
Japan	269,110	699,110	Y
India	169,800	489,840	Y
Canada	6,360	21,140	Y
Iran	TBD	TBD	Y
New Zealand	5,300	11,190	N (advanced discussions underway)
TOTAL			

Disclaimer

The logo for Memphasys, featuring a stylized graphic of overlapping circles in white and grey on a dark blue background, followed by the word "Memphasys" in a blue sans-serif font.

Memphasys

This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell Memphasys securities or other products should be made only after seeking appropriate financial advice. Reliance should not be placed on information or opinions contained in this presentation and subject only to any legal obligation to do so, the Company does not accept any obligation to correct or update them.

This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor.

To the fullest extent permitted by law, Memphasys and its affiliates and their

respective officers, directors, employees and agents, accept no responsibility for any information provided in this presentation, including any forward looking information, and disclaim and liability whatsoever (including for negligence) for any loss howsoever arising from any use of this presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this presentation.

Thank you

Alison Coutts

Executive Chairman, *Memphasys Ltd*

30-32 Richmond Rd, Homebush NSW 2140 Australia

Phone: +612 8415 7300